Histone-associated nuclear antigens on necrotic tumor cells (TNT antigens)

Histone-associated nuclear antigens on necrotic tumor cells represent a unique class of therapeutic targets found within the necrotic core of solid tumors. In healthy cells, these antigens (primarily histone H1 and DNA-histone complexes) are sequestered within the nucleus and protected by intact plasma and nuclear membranes. However, in the hypoxic and nutrient-deprived centers of rapidly growing tumors, cells undergo necrosis, leading to membrane disintegration and the exposure of these abundant nuclear proteins. This exposure allows specialized monoclonal antibodies, known as Tumor Necrosis Therapy (TNT) antibodies, to bind specifically to the necrotic regions of the tumor. By targeting these universal antigens, TNT-based therapies can deliver cytotoxic payloads, such as radioisotopes or immunostimulatory cytokines, directly to the tumor site regardless of the specific tumor cell surface markers. This approach is particularly effective in large, poorly vascularized solid tumors where conventional therapies often fail to reach the necrotic center.

Other names

Necrotic tumor antigensNuclear antigens in necrotic tissueHistone-DNA complexTNT-1 targetTNT-2 targetTNT-3 target

Monoclonal antibodies (Tumor Necrosis Therapy or TNT) bind to histone-DNA complexes that become accessible only in the necrotic core of solid tumors due to the loss of cell membrane integrity. These antibodies serve as delivery vehicles for radioisotopes (e.g., Iodine-131) or cytokines (e.g., IL-2, IFN-gamma) to the tumor microenvironment, inducing localized cell death or immune activation.